SR One Capital Management
SR One Capital Management reported 15 stocks worth $1B in its 13F filing for Q2 2026, filed Aug 12, 2026. Its largest holdings are MANE (28.4%), ZBIO (12.3%) and CRSP (10.7%). Compared with Q1 2026, the fund opened new positions in AVLN, ODTX and MOBI, added to ORIC and sold out of ORKA.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  MANE Veradermics Inc | $295M | 28.4% | 2.4M | No change | 2 of 8 | |
| 2 |  ZBIO Zenas Biopharma Inc | $128M | 12.3% | 5M | No change | 8 of 8 | |
| 3 |  CRSP Crispr Therapeutics | $111M | 10.7% | 2M | No change | 8 of 8 | |
| 4 |  AVLN Avalyn Pharma Inc | $109M | 10.5% | 3.3M | New position | 1 of 8 | |
| 5 |  DSGN Design Therapeutics Inc | $94.4M | 9.1% | 6.5M | No change | 8 of 8 | |
| 6 |  ODTX Odyssey Therapeutics, Inc. | $71M | 6.8% | 3.8M | New position | 1 of 8 | |
| 7 |  ALMS Alumis Inc | $55.2M | 5.3% | 2M | No change | 8 of 8 | |
| 8 |  ORIC Oric Pharmaceuticals Inc | $50M | 4.8% | 4.6M | +100K (+2%) | 5 of 8 | |
| 9 |  MLYS Mineralys Therapeutics Inc | $42.2M | 4.1% | 1.6M | No change | 8 of 8 | |
| 10 |  SPRY Ars Pharmaceuticals Inc | $32.1M | 3.1% | 4M | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
ARCELLX INC | $269M | 2.3M |
 ORKA Oruka Therapeutics Inc | $21.1M | 430K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 12, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →SR One Capital Management 13F FAQ
What does SR One Capital Management own?
SR One Capital Management reported 15 stocks worth $1B in its 13F filing for Q2 2026, filed Aug 12, 2026. Its largest holdings are MANE (28.4%), ZBIO (12.3%) and CRSP (10.7%). The table above lists every position in the filing (the top 10 without an account).
What did SR One Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 3 new positions, 1 added to, 0 trimmed and 2 sold out. New positions include AVLN, ODTX and MOBI. It sold all of ORKA.
When will SR One Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is SR One Capital Management's portfolio worth?
The Q2 2026 filing reports $1B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.